In 2019, entrectinib, a pan-TRK inhibitor, was approved for use against ROS1–positive NSCLC fusions based on its 77% ORR in clinical trials and ability to penetrate the central nervous system, making it suitable for ROS1-fusion NSCLC patients who experienced brain metastasis [77]. This evidence concerns the gene NTRK1 and non-small cell lung carcinoma.